PMID- 24595937
OWN - NLM
STAT- MEDLINE
DCOM- 20141114
LR  - 20201005
IS  - 1735-546X (Electronic)
IS  - 1735-1308 (Linking)
VI  - 11
IP  - 1
DP  - 2014 Mar 4
TI  - Is there a relationship between acute coronary syndrome and prostate specific 
      antigen level?
PG  - 1278-86
AB  - PURPOSE: Interestingly, prostate-specific antigen (PSA), which is used to monitor 
      prostate disorders, has been suggested to be beneficial in estimating prognosis 
      associated with coronary artery disease (CAD). The aim of the present study was 
      to investigate the relationship of serum levels of PSA and free PSA (fPSA) with 
      prognosis of acute coronary syndromes (ACS), extent of CAD and major adverse 
      cardiac events in patients with acute coronary syndromes. MATERIALS AND METHODS: 
      Sixty-seven male patients who were diagnosed with acute coronary syndromes were 
      included. All patients were assessed according to the Thrombolysis in Myocardial 
      Infarction (TIMI) classification [ST elevation myocardial infarction (STEMI) and 
      non-ST elevation (NSTE)-ACS groups, separately], the Global Registry of Acute 
      Cardiac Events (GRACE) (difference between PSA and fPSA) risk score and the 
      Killip classification. All patients underwent angiography. The degree of stenosis 
      was scored using the Gensini score to assess the extent of CAD. RESULTS: Serum 
      PSA, fPSA, fPSA/PSA levels, and alpha 1-antichymotrypsin-PSA (ACT-PSA) 
      (difference between PSA and fPSA) results were found to be moderately correlated 
      with the TIMI and GRACE risk scores, which are predictors of short- and mid-term 
      prognosis. While there was no correlation between the Gensini score and PSA and 
      ACT-PSA, the Gensini score was moderately correlated with fPSA and fPSA/PSA. 
      There were no significant differences between patients with major adverse 
      cardiovascular events (MACEs) and those without MACEs at the 6-month follow-up in 
      terms of PSA, fPSA, fPSA/PSA, and ACT-PSA results. CONCLUSION: There may be a 
      relationship between serum PSA and fPSA levels and prognosis of ACS and extent of 
      CAD. It should be kept in mind that additional biomarkers could be used together 
      with current scoring systems in risk classification in cases for which clinical 
      decision-making is challenging. Moreover, PSA and fPSA results should be 
      approached with caution in patients to be screened for prostate cancer as their 
      serum levels may be influenced from several factors (ACS, infection, etc.).
FAU - Durmaz, Tahir
AU  - Durmaz T
AD  - Department of Cardiology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey.
FAU - Ayhan, Huseyin
AU  - Ayhan H
AD  - Department of Cardiology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey. huseyinayhan44@yahoo.com.
FAU - Keles, Telat
AU  - Keles T
AD  - Department of Cardiology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey.
FAU - Bilen, Emine
AU  - Bilen E
AD  - Department of Cardiology, Ankara Ataturk Education and Research Hospital, Ankara, 
      Turkey.
FAU - Akcay, Murat
AU  - Akcay M
AD  - Department of Cardiology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey.
FAU - Akar Bayram, Nihal
AU  - Akar Bayram N
AD  - Department of Cardiology, Ankara Ataturk Education and Research Hospital, Ankara, 
      Turkey.
FAU - Bozkurt, Engin
AU  - Bozkurt E
AD  - Department of Cardiology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20140304
PL  - Iran
TA  - Urol J
JT  - Urology journal
JID - 101286676
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - Urol J. 2014 Jan-Feb;11(1):1287-8. PMID: 24595938
MH  - Acute Coronary Syndrome/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood
EDAT- 2014/03/07 06:00
MHDA- 2014/11/15 06:00
CRDT- 2014/03/06 06:00
PHST- 2012/09/22 00:00 [received]
PHST- 2013/03/11 00:00 [accepted]
PHST- 2013/01/06 00:00 [revised]
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/11/15 06:00 [medline]
AID - 1657 [pii]
PST - epublish
SO  - Urol J. 2014 Mar 4;11(1):1278-86.